Prothena Stock Forecast, Price & News

+2.64 (+5.27 %)
(As of 08/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume202,422 shs
Average Volume458,356 shs
Market Capitalization$2.33 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Prothena logo

About Prothena

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.48 out of 5 stars

Medical Sector

118th out of 2,226 stocks

Pharmaceutical Preparations Industry

60th out of 870 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Prothena (NASDAQ:PRTA) Frequently Asked Questions

Is Prothena a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Prothena stock.
View analyst ratings for Prothena
or view top-rated stocks.

What stocks does MarketBeat like better than Prothena?

Wall Street analysts have given Prothena a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prothena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Prothena?

Prothena saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 1,630,000 shares, a drop of 23.8% from the June 15th total of 2,140,000 shares. Based on an average trading volume of 463,500 shares, the short-interest ratio is currently 3.5 days. Currently, 3.7% of the company's shares are short sold.
View Prothena's Short Interest

When is Prothena's next earnings date?

Prothena is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Prothena

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) issued its quarterly earnings data on Monday, May, 10th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.11. The biotechnology company had revenue of $0.16 million for the quarter, compared to analysts' expectations of $0.17 million. Prothena had a negative trailing twelve-month return on equity of 57.65% and a negative net margin of 14,255.73%.
View Prothena's earnings history

How has Prothena's stock been impacted by Coronavirus?

Prothena's stock was trading at $9.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRTA shares have increased by 442.6% and is now trading at $52.74.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PRTA?

8 analysts have issued 1-year price objectives for Prothena's stock. Their forecasts range from $38.00 to $76.00. On average, they anticipate Prothena's share price to reach $63.00 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price.
View analysts' price targets for Prothena
or view top-rated stocks among Wall Street analysts.

Who are Prothena's key executives?

Prothena's management team includes the following people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 52, Pay $901.12k)
  • Mr. Tran B. Nguyen M.B.A., CFO & COO (Age 47, Pay $679.37k)
  • Mr. Michael J. Malecek, Chief Legal Officer & Company Sec. (Age 55, Pay $588.25k)
  • Ms. Carol D. Karp, Chief Regulatory Officer (Age 68, Pay $624.39k)
  • Mr. Brandon S. Smith, Chief Bus. Officer (Age 46, Pay $580.92k)
  • Ms. Karin L. Walker CPA, Chief Accounting Officer & Controller (Age 58)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 48)
  • Ms. Jennifer Zibuda, Director of Investor Relations & Communication
  • Dr. Radhika Tripuraneni M.P.H., M.D., Chief Devel. Officer (Age 41)
  • Dr. Hideki Garren, Chief Medical Officer (Age 56)

Who are some of Prothena's key competitors?

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by a variety of retail and institutional investors. Top institutional investors include Pinnacle Associates Ltd. (0.47%), Hillsdale Investment Management Inc. (0.12%), Alliancebernstein L.P. (0.11%), Hunter Perkins Capital Management LLC (0.01%) and Focused Wealth Management Inc (0.01%). Company insiders that own Prothena stock include Christopher S Henney, Dennis J Selkoe, Ecor1 Capital, Llc and Wagner M Zago.
View institutional ownership trends for Prothena

Which major investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., and Focused Wealth Management Inc. Company insiders that have sold Prothena company stock in the last year include Christopher S Henney, Dennis J Selkoe, and Wagner M Zago.
View insider buying and selling activity for Prothena
or view top insider-selling stocks.

Which major investors are buying Prothena stock?

PRTA stock was purchased by a variety of institutional investors in the last quarter, including Hillsdale Investment Management Inc., Alliancebernstein L.P., and Hunter Perkins Capital Management LLC.
View insider buying and selling activity for Prothena
or or view top insider-buying stocks.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $52.74.

How much money does Prothena make?

Prothena has a market capitalization of $2.33 billion and generates $850,000.00 in revenue each year. The biotechnology company earns $-111,140,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Prothena have?

Prothena employs 66 workers across the globe.

What is Prothena's official website?

The official website for Prothena is

Where are Prothena's headquarters?

Prothena is headquartered at 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.